31May

Savolitinib can be a better treatment choice than sunitinib due to its improved efficacy and safety profile

SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).


Abstract No : 5002

Abstract Type : Oral Abstract Session

Indication : Papillary Renal Cell Carcinoma (PRCC)

Intervention : Savolitinib

Company : AstraZeneca

Technology : c-MET Tyrosine Kinase Inhibitor


Results:

After external data on predicted PFS with sunitinib in pts with MET-driven disease became available, study enrollment was closed. At data cutoff (Aug 2019), only 60 of the planned 180 pts were randomized (savolitinib n = 33; sunitinib n = 27). Most had chromosome 7 gain (savolitinib 91%; sunitinib 96%) and no prior therapy (savolitinib 85%; sunitinib 93%). PFS, OS, and ORR were numerically improved with savolitinib vs sunitinib (Table). CTCAE grade $3 adverse events (AEs) were reported in 42% and 81% of pts; dose modifications were related to AEs in 30% and 74% of pts with savolitinib and sunitinib respectively. After discontinuation, 36% of all savolitinib and 19% of all sunitinib pts received subsequent anticancer therapy


Conclusion:

Although pt numbers and followup were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile vs sunitinib, with fewer grade $3 AEs and fewer dose modifications required. Sunitinib performance was poorer than expected based on external retrospective data. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted


Commentary:

Savolitinib demonstrated encouraging efficacy and an improved safety profile vs sunitinib, with fewer grade 3 AEs and fewer dose modifications required. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.


Refer to Renal Cell Carcinoma Market report for detailed Insights.